TruScreen revenue stalled at NZ$0.7m as cash halved to NZ$1.7m

What changed

Revenue from continuing operations was effectively flat at NZ$0.7m (-0.7% on HY22's NZ$0.7m), with management framing this as holding the line against challenging conditions including COVID-Zero disruption in China. The reported loss narrowed marginally to NZ$1.2m from NZ$1.3m (PBT +3.1%), with no tax line in either period. Operating cash outflow improved 29.3% to NZ$1.2m from NZ$1.7m. The bigger movements were on the balance sheet: cash fell 54.3% to NZ$1.7m from NZ$3.7m, total equity dropped 76.1% to NZ$2.3m, and trade receivables ballooned from NZ$6.7k to NZ$150.4k. There are still no borrowings and no dividend.

What matters

• Cash runway is now the defining issue. At a HY23 operating burn of NZ$1.2m and only NZ$1.7m of cash on hand, the implied runway at current pace is roughly one to one-and-a-half halves before further capital is required. That reframes the "revenue held up" narrative.
• Receivables quality has shifted abruptly. Trade receivables went from NZ$6.7k to NZ$150.4k, taking receivable days from ~1.6 to ~37. On a NZ$0.7m revenue base that is roughly 20% of the half's revenue sitting in debtors, which both flatters reported revenue versus cash collected and introduces concentration/credit risk that is not separately disclosed.
• The revenue base remains sub-scale and is going backwards versus FY22. Annualising HY23 implies ~NZ$1.5m of revenue against an FY22 anchor of NZ$1.7m. For a healthcare device business still trying to demonstrate operating leverage, a flat half-year against a tough comp is not yet evidence of a scale inflection.

Expectations

No quantitative guidance, order book, or stated targets were provided. FY22 was heavily second-half weighted (HY22 was only 44.4% of FY22 revenue and 16% of full-year NPAT), so a flat first half does not by itself rule out a stronger second half — but it also offers no concrete support for one. Management cited China's private health-check channel and Made-in-China device sales as positives, but did not quantify a pipeline. On the figures supplied, the release supports a "revenue stabilised at a low base" reading, not a re-acceleration thesis.

Quality of result

The headline improvements are thin and partly mechanical. The 3.1% loss reduction is on a NZ$1.2m base, so absolute progress is NZ$39k. The 29.3% improvement in operating cash burn is genuine in direction but is partly explained by NZ$143.8k more cash held back in receivables — collections, not earnings, would have been worse. With no gross margin, segment, or non-GAAP disclosure provided, and capex at zero, there is no evidence of operating leverage emerging; the result reads as cost discipline against a flat top line rather than scale-driven margin progress. Per the sector lens, this is still very much a pre-scale launch profile, not a durable earnings stream.

Unresolved

• Why did receivables jump from NZ$6.7k to NZ$150.4k, who owes it, and on what terms?
• What is the funding plan given NZ$1.7m of cash against ~NZ$1.2m of half-yearly operating burn?
• What drove the NZ$7.4m fall in total assets and NZ$7.3m fall in equity year on year — capital structure changes, write-downs, or accumulated losses absorbing reserves are not separately explained in the supplied excerpts.
• What is the actual H2 pipeline in China's private health-check channel and Eastern Europe in unit/dollar terms?
• Is there any customer or geographic concentration behind the flat revenue line?

This briefing cannot assess product-level margins, regulatory pipeline, or any post-period capital-raising or commercial milestones, none of which were disclosed in the supplied materials.

Key metrics

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.